Literature DB >> 19662498

Dephosphorylation and inactivation of Akt/PKB is counteracted by protein kinase CK2 in HEK 293T cells.

Giovanni Di Maira1, Francesca Brustolon, Lorenzo A Pinna, Maria Ruzzene.   

Abstract

Akt (PKB) is a critical kinase in cell-survival pathways. Its activity depends on the phosphorylation of Thr308 and Ser473, by PDK1 and mTORC2, respectively. We found that Akt can be further stimulated through phosphorylation of Ser129 by another kinase, CK2. Here we show that phosphorylation of Akt at Ser129 also facilitates its association with Hsp90 chaperone, thus preventing Thr308 dephosphorylation. This is supported by the following observations: (1) phospho-Thr308 decreases when Ser129 is mutated to alanine, (2) this decrease is abolished by cell treatment with okadaic acid (to inactivate PP2A) or geldanamycin (to inactivate Hsp90), (3) phosphorylation of Ser129 neither enhances the activity of PDK1 nor hampers the in vitro activity of PP2A on Thr308, but increases the Hsp90 association to Akt. These data support the view that the antiapoptotic potential of CK2 is at least in part mediated by its ability to maintain Akt in its active form.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19662498     DOI: 10.1007/s00018-009-0108-1

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  41 in total

1.  The protooncogene TCL1 is an Akt kinase coactivator.

Authors:  J Laine; G Künstle; T Obata; M Sha; M Noguchi
Journal:  Mol Cell       Date:  2000-08       Impact factor: 17.970

Review 2.  Protein kinase CK2: a challenge to canons.

Authors:  Lorenzo A Pinna
Journal:  J Cell Sci       Date:  2002-10-15       Impact factor: 5.285

Review 3.  Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2.

Authors:  James S Duncan; David W Litchfield
Journal:  Biochim Biophys Acta       Date:  2007-08-30

4.  Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.

Authors:  G Di Maira; F Brustolon; J Bertacchini; K Tosoni; S Marmiroli; L A Pinna; M Ruzzene
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

5.  Modulation of Akt kinase activity by binding to Hsp90.

Authors:  S Sato; N Fujita; T Tsuruo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

6.  Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors.

Authors:  M Andjelković; T Jakubowicz; P Cron; X F Ming; J W Han; B A Hemmings
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

Review 7.  Okadaic acid: a new probe for the study of cellular regulation.

Authors:  P Cohen; C F Holmes; Y Tsukitani
Journal:  Trends Biochem Sci       Date:  1990-03       Impact factor: 13.807

Review 8.  Targeting CK2 for cancer therapy.

Authors:  Kashif A Ahmad; Guixia Wang; Joel Slaton; Gretchen Unger; Khalil Ahmed
Journal:  Anticancer Drugs       Date:  2005-11       Impact factor: 2.248

9.  Protein kinase CK2 impairs spatial memory formation through differential cross talk with PI-3 kinase signaling: activation of Akt and inactivation of SGK1.

Authors:  Chih C Chao; Yun L Ma; Eminy H Y Lee
Journal:  J Neurosci       Date:  2007-06-06       Impact factor: 6.167

10.  Protein kinase CK2 subunits are positive regulators of AKT kinase.

Authors:  Barbara Guerra
Journal:  Int J Oncol       Date:  2006-03       Impact factor: 5.650

View more
  23 in total

1.  Identification of novel CK2 inhibitors with a benzofuran scaffold by novel non-radiometric in vitro assays.

Authors:  Andreas Gratz; Uwe Kuckländer; Ricardo Bollig; Claudia Götz; Joachim Jose
Journal:  Mol Cell Biochem       Date:  2011-07-13       Impact factor: 3.396

2.  Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA.

Authors:  Le Xuan Truong Nguyen; Beverly S Mitchell
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

3.  Potent and Selective CK2 Kinase Inhibitors with Effects on Wnt Pathway Signaling in Vivo.

Authors:  James E Dowling; Marat Alimzhanov; Larry Bao; Claudio Chuaqui; Christopher R Denz; Emma Jenkins; Nicholas A Larsen; Paul D Lyne; Timothy Pontz; Qing Ye; Geoff A Holdgate; Lindsay Snow; Nichole O'Connell; Andrew D Ferguson
Journal:  ACS Med Chem Lett       Date:  2016-01-20       Impact factor: 4.345

4.  Potent and Selective Inhibitors of CK2 Kinase Identified through Structure-Guided Hybridization.

Authors:  James E Dowling; Claudio Chuaqui; Timothy W Pontz; Paul D Lyne; Nicholas A Larsen; Michael H Block; Huawei Chen; Nancy Su; Allan Wu; Daniel Russell; Hannah Pollard; John W Lee; Bo Peng; Kumar Thakur; Qing Ye; Tao Zhang; Patrick Brassil; Vicki Racicot; Larry Bao; Christopher R Denz; Emma Cooke
Journal:  ACS Med Chem Lett       Date:  2012-01-24       Impact factor: 4.345

5.  Structure and Property Based Design of Pyrazolo[1,5-a]pyrimidine Inhibitors of CK2 Kinase with Activity in Vivo.

Authors:  James E Dowling; Marat Alimzhanov; Larry Bao; Michael H Block; Claudio Chuaqui; Emma L Cooke; Christopher R Denz; Alex Hird; Shan Huang; Nicholas A Larsen; Bo Peng; Timothy W Pontz; Caroline Rivard-Costa; Jamal Carlos Saeh; Kumar Thakur; Qing Ye; Tao Zhang; Paul D Lyne
Journal:  ACS Med Chem Lett       Date:  2013-07-03       Impact factor: 4.345

6.  Kinase inhibitors modulate huntingtin cell localization and toxicity.

Authors:  Randy Singh Atwal; Carly R Desmond; Nicholas Caron; Tamara Maiuri; Jianrun Xia; Simonetta Sipione; Ray Truant
Journal:  Nat Chem Biol       Date:  2011-05-29       Impact factor: 15.040

7.  Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.

Authors:  F Buontempo; E Orsini; L R Martins; I Antunes; A Lonetti; F Chiarini; G Tabellini; C Evangelisti; C Evangelisti; F Melchionda; A Pession; A Bertaina; F Locatelli; J A McCubrey; A Cappellini; J T Barata; A M Martelli
Journal:  Leukemia       Date:  2013-11-20       Impact factor: 11.528

8.  Enhancing chemosensitivity to gemcitabine via RNA interference targeting the catalytic subunits of protein kinase CK2 in human pancreatic cancer cells.

Authors:  Jan N Kreutzer; Maria Ruzzene; Barbara Guerra
Journal:  BMC Cancer       Date:  2010-08-19       Impact factor: 4.430

Review 9.  Targeting CK2-driven non-oncogene addiction in B-cell tumors.

Authors:  E Mandato; S Manni; F Zaffino; G Semenzato; F Piazza
Journal:  Oncogene       Date:  2016-04-04       Impact factor: 9.867

10.  Cyclooxygenase 2-dependent and independent activation of Akt through casein kinase 2α contributes to human bladder cancer cell survival.

Authors:  Keiji Shimada; Satoshi Anai; Develasco A Marco; Kiyohide Fujimoto; Noboru Konishi
Journal:  BMC Urol       Date:  2011-05-18       Impact factor: 2.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.